Bank of America
RSLS

Bank of America’s ReShape Lifesciences Inc. Common Stock RSLS Stock Holding History

Bank of America’s Portfolio RSLS Stock Details RSLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-3
Closed -$1K – 7626
2018
Q2 		$1K Buy
+3
New +$2.56K ﹤0.01% 7030
2018
Q1 		– Hold
0
– – – 7495
2017
Q4 		– Hold
0
– – – 7422

Other funds holding RSLS

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
IBT
International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America's RSLS Position: Q3 2018 in Review

Bank of America sold out of ReShape Lifesciences Inc. Common Stock (RSLS) in Q3 2018, closing a stake of 3 shares — an estimated $1K sold.

Bank of America first reported a position in RSLS in Q2 2018 and held it in 1 quarter. The position peaked at $1K in Q2 2018. 15 funds tracked by Wall St. Rank hold RSLS as of Q3 2018.

  • Bank of America reported no remaining ReShape Lifesciences Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • Bank of America sold 3 ReShape Lifesciences Inc. Common Stock shares in Q3 2018, an estimated $1K.
  • Bank of America first reported a position in ReShape Lifesciences Inc. Common Stock in Q2 2018 and held it in 1 quarter.
  • Bank of America's ReShape Lifesciences Inc. Common Stock position peaked at $1K in Q2 2018.
  • 15 funds tracked by Wall St. Rank held ReShape Lifesciences Inc. Common Stock as of Q3 2018.

Based on Bank of America's 13F filing for Q3 2018, filed 14 Nov 2018.